Immunicum AB (publ) Announces Appointment of Sharon Longhurst as Head of CMC
October 10 2017 - 2:00AM
YASTESTPress Release
10 October 2017
Immunicum AB (publ) Announces Appointment of Sharon Longhurst as
Head of CMC
Immunicum AB
(publ; First North Premier: IMMU.ST) a biopharmaceutical company
advancing a novel, immune-priming cancer treatment against a
variety of solid tumors, today announced the appointment of Sharon
Longhurst as Head of Chemistry, Manufacturing and Controls
(CMC).
Dr. Longhurst comes to Immunicum
with over 15 years in leading CMC efforts in small and medium sized
organizations. Most recently she served as Senior CMC Manager at
Akari Therapeutics in addition to having been a senior
pharmaceutical assessor for the Medicines & Healthcare Products
Regulatory Agency (MHRA) in London. Sharon will replace Karin
Hoogendoorn, who has been extended the opportunity to return to
academia.
"Sharon's insights on advanced
therapy manufacturing and CMC strategy will support Immunicum's
proposed plan to develop a commercially-ready CMC process for our
lead product candidate, ilixadencel," said Carlos de Sousa, CEO of
Immunicum. "We are happy for Karin's new career opportunity and we
wish her all the best."
"I am delighted to join Immunicum
at this exciting stage of development for ilixadencel," said Sharon
Longhurst. "The potential for ilixadencel as an immune system
primer in multiple cancer indications is an exciting prospect that
could make a tremendous difference to those diagnosed and I very
much look forward to contributing to its further success in the
clinic by bringing to the company my CMC experience with biological
products, in particular manufacturing and regulatory experience
with cell based therapy products."
Sharon Longhurst joins Immunicum
from her previous position as Senior CMC Manager at Akari
Therapeutics, where she was responsible for all aspects of CMC for
an innovative biologic product, Coversin, including clinical supply
and distribution. Prior to that, Sharon spent 5 years as Principal
Consultant of CMC at Parexel Consulting. From 2005-2011, she was a
Pharmaceutical Assessor at MHRA in London in the
biologics/biotechnology unit and provided national and EU
scientific advice for Advance Therapy Medicinal Products (ATMPs)
for cell and gene therapy. Sharon graduated from the University of
Warwick, Coventry, UK with a PhD in Virology.
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Investor Relations Sweden
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: ir@immuicum.com
Investor and Media Relations EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or +49 175 5711562
E-mail: ir@immunicum.com
The Company's Certified Adviser is Redeye
AB
Telephone: +46 (0)8 545 013 30
www.redeye.se
About Immunicum AB (publ) Immunicum is establishing a unique
immuno-oncology approach through the development of allogeneic,
off-the-shelf cell-based therapies. Our goal is to improve survival
outcomes and quality of life by priming the patient's own immune
system to fight cancer. The company's lead product ilixadencel,
consisting of pro-inflammatory allogeneic dendritic cells, has the
potential to become a backbone component of modern cancer
combination treatments in a variety of solid tumor indications.
Founded and based in Sweden, Immunicum is publicly traded on the
Nasdaq First North Premier. www.immunicum.com
|
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Sep 2023 to Sep 2024